Key Takeaway: The ASGCT Annual Meeting featured a poster presentation on Immuno-STAT™ stimulation, which aims to enhance CAR T cell expansion and persistence through TCR and IL-2 signaling. This innovative approach showcases potential advancements in immunotherapy. The meeting serves as a platform for sharing cutting-edge research in the field.
Price reaction · baseline $21.213 (2025-05-22 close) · hit pre-market · clean, no other CUE news in the window
day 0 close
-6.5%
day 1
-6.2%
day 3 · peak
-8.9%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on innovative CAR T cell therapies.
Presentation highlights advancements in immunotherapy.
Engagement with the scientific community at ASGCT.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+253%
120-day peak, hindsight
Typical move
10.2%
average across 2 past catalysts
Cash runway
~2 mo
High dilution risk
Lead asset
CUE-101
Phase 2 · Head and Neck Squamous Cell Carcinoma
Full Press Release Details
ASGCT Annual Meeting
Poster Presentation: Leveraging Immuno-STAT™ stimulation via TCR and IL-2 signaling to specifically control CAR T cell expansion and persistence in vivo
• About Us
• Pipeline
• News
• Investors
• Contact Us
Frequently Asked Questions
What was presented at the ASGCT Annual Meeting?
A poster presentation on Immuno-STAT™ stimulation for CAR T cell therapy.
What is Immuno-STAT™?
Immuno-STAT™ is a method to enhance CAR T cell expansion and persistence.
What are the key signaling pathways discussed?
The presentation focused on TCR and IL-2 signaling pathways.
Who organized the ASGCT Annual Meeting?
The meeting was organized by the American Society of Gene & Cell Therapy.